Intensity Modulated Radiation Therapy

Coverage Summary

Policy 0590 (effective 02/12/2002; last reviewed 09/07/2023; next review 06/27/2024) covers Intensity‑Modulated Radiation Therapy (IMRT) and related services. The policy stance is covered with criteria: IMRT (and placement of fiducial markers or use of inter-/intrafraction image guidance) is medically necessary only when specified selection criteria are met. Key threshold definitions include: IMRT is defined as radiation therapy requiring highly sophisticated planning using numerous beamlets to meet dose requirements to tumor and organs at risk; and a critical‑structure benefit is present when IMRT would reduce the probability of grade 2 or 3 radiation toxicity versus 3D CRT in greater than 15% of similar cases. Dose thresholds for certain sites are specified (e.g., esophagus, gallbladder, pancreas: planned dose > 50 Gy).

Key thresholds and definitions

Policy number0590

PayerAetna

Definition of IMRT critical-structure benefit thresholdIMRT would decrease the probability of grade 2 or grade 3 radiation toxicity vs 3D CRT in greater than 15% of similar cases

Dose threshold for esophageal/gallbladder/pancreatic indications> 50 Gy

IMRT definition (planning requirement)Radiation therapy requiring highly sophisticated treatment planning utilizing numerous beamlets to generate dosimetry per assigned dose requirements to tumor and organs at risk

Medical-Necessity Criteria

Medical Necessity

Aetna considers the following interventions medically necessary:

Medical Necessity - required items

IMRT requirement: Intensity modulated radiation therapy (IMRT) for certain indications where critical structures cannot be adequately protected with standard 3-dimensional (3D) conformal radiotherapy
Policy statement
Fiducial markers: Placement of fiducial markers if the above criteria are met, and the radiation target is not clearly visible, and bony anatomy is not sufficient for adequate target alignment
Placement permitted only if IMRT criteria are met
Image guidance: Interfraction image guidance or intrafraction image guidance systems (e.g., Calypso 4D Localization System, RayPilot System) for delivering IMRT and other conformal radiotherapy

Not Medically Necessary / Experimental

Exclusions: IMRT is considered experimental, investigational, and not medically necessary for the following:

Not medically necessary / experimental

Right breast: IMRT is considered experimental and not medically necessary for right breast cancer
Other indications not listed: IMRT is considered experimental and investigational for all other indications not listed as medically necessary

Coding

Covered CPT codes if selection criteria are metCPTCovered

32553	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), percutaneous, intra-thoracic, single or multiple.
49327	Laparoscopy, surgical; with placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), intra-abdominal, intrapelvic, and/or retroperitoneum, including imaging guidance, if performed, single or multiple (List separately in addition to code for primary procedure).
49411	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), percutaneous, intra-abdominal, intra-pelvic (except prostate), and/or retroperitoneum, single or multiple.
49412	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), open, intra-abdominal, intrapelvic, and/or retroperitoneum, including image guidance, if performed, single or multiple (List separately in addition to code for primary procedure).
77301	Intensity modulated radiotherapy planning, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (MRT), design and construction per IMRT plan.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed.
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed.
77387	Guidance for localization of target volume for delivery of radiation treatment delivery, includes intrafraction tracking, when performed.

Covered HCPCS codes if selection criteria are metHCPCSCovered

A4648	Tissue marker, implantable, any type, each.
C9728	Placement of interstitial device(s) for radiation therapy/surgery guidance (eg, fiducial markers, dosimeter), for other than the following sites (any approach): abdomen, pelvis, prostate, retroperitoneum, thorax, single or multiple.
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session.
G6017	Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment.

Covered ICD-10 codes if selection criteria are metICD-10Covered

C00.0-D49.9	Neoplasms (range)
Z51.0	Encounter for antineoplastic radiation therapy

No procedure/diagnosis codes listed in this partmixed

No codes listed

Provider Actions

Prior Authorization

Medical necessity requirement

IMRT is authorized only for the indications listed as medically necessary in the policy. Providers must document why IMRT is required for the case — e.g., proximity of the target to critical structures, prior irradiation requiring abutting portals, need for dose escalation, concave/complex target geometry, or other rationale demonstrating that 3D CRT cannot adequately protect critical structures.

Documentation Required

Apply eviCore radiation therapy clinical guidelines

Follow eviCore Healthcare Radiation Therapy Clinical Guidelines for medical necessity criteria. eviCore determines the specific indications and selection criteria for IMRT and is the reference for prior authorization decisions.

Background & Evidence

Background: IMRT is a highly sophisticated radiotherapy technique that uses inverse planning and numerous beamlets to produce highly conformal dose distributions that spare adjacent organs at risk. Delivery approaches include dynamic multileaf collimators (MLCs) that modulate beam intensity during treatment and compensator‑based techniques that use custom high‑density modulators to shape the beam. Fiducial markers (e.g., gold seeds, stainless steel screws, or electromagnetic transponders) may be implanted to improve target localization when the target is not clearly visible and bony anatomy is insufficient. Potential benefits include improved critical‑structure sparing and the ability to escalate dose or treat complex/concave targets; potential risks include increased whole‑body or low‑dose exposure with theoretical higher secondary malignancy risk, the possibility of geographic miss with overly tight margins, and added imaging exposure from frequent image guidance. Because IMRT planning and delivery are technically demanding, appropriate expertise, image‑guidance, and quality assurance are required and some uses are recommended to be limited to experienced centers.

Study/Guidance	Key finding
KCE assessment (Van den Steen et al, 2007)	Found weak-to-moderate evidence of toxicity reduction in head/neck, prostate, breast; recommended restriction to experienced centers and need for more long-term data; noted potential increased secondary malignancy risk.
Pignol et al (2008) — RCT in breast cancer	BIMRT reduced acute skin toxicity (moist desquamation) compared with wedge compensation.
Donovan et al (2007) — RCT in breast cancer	BIMRT associated with fewer late adverse effects and better cosmetic outcomes versus wedge compensation/2D RT.
Romesser et al (2021) — prospective phase II, thyroid cancer	IMRT ± concurrent doxorubicin showed 2-year locoregional PFS 79.7%; CC-IMRT had less locoregional failure in post-hoc analysis but small nonrandomized sample (n=27).
Wu et al (2022) — phase II neoadjuvant IMRT in centrally located HCC	Promising 1-, 3-, 5-year OS (94.6%, 75.4%, 69.1%) with acceptable toxicity in single-arm trial (n=38).
ASTRO coding guide / expert panels	Lists common indications supporting IMRT (prostate, CNS, head/neck, select breast, selected thoracic/abdominal, pelvic/retroperitoneal tumors) and clinical planning considerations.

Definitions

Definitions (policy terms)

IMRTFor this policy, radiation therapy requiring highly sophisticated treatment planning utilizing numerous beamlets to generate dosimetry in accordance with assigned dose requirements to the tumor and organs at risk.

IGRTImage-guided radiation therapy, which may include CT, MRI, ultrasound, or X-ray used to direct and guide delivery of radiation (used for planning, setup verification/correction, and follow-up).

Critical structures inadequately protectedSituations where IMRT would decrease probability of grade 2 or grade 3 radiation toxicity vs 3D CRT in >15% of similar cases.

OpenPayer